Related Experiment Videos
Antiallergics: 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-ones
Journal of Medicinal Chemistry
|July 1, 1982
Summary
New pyrimidobenzothiazole compounds show potent antiallergic and bronchodilator effects. These agents outperformed disodium chromoglycate and theophylline in rat models, indicating significant therapeutic potential.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Allergic diseases and asthma represent significant global health burdens.
- Development of novel therapeutic agents with both antiallergic and bronchodilator properties is crucial.
Purpose of the Study:
- To synthesize and evaluate a novel series of pyrimido[2,1-b]benzothiazole derivatives.
- To assess the antiallergic and bronchodilator activities of these compounds.
Main Methods:
- Synthesis of a short series of 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-one derivatives.
- Evaluation of oral antiallergic activity using the rat passive cutaneous anaphylaxis (PCA) test.
- Assessment of bronchodilator activity.
Main Results:
- The parent compound, 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-one, and its 8-chloro derivative demonstrated significant oral antiallergic activity in the rat PCA test.
- Both compounds exhibited superior potency compared to disodium chromoglycate and theophylline as antiallergic agents.
- Significant bronchodilator activity was also observed for these two lead compounds.
Conclusions:
- The synthesized pyrimido[2,1-b]benzothiazole derivatives possess promising antiallergic and bronchodilator properties.
- The 8-chloro derivative and the parent compound are particularly potent and warrant further investigation as potential therapeutics for allergic and respiratory diseases.